Charles River & Toxys Launch ReproTracker: Non-Animal Developmental Toxicity Test
Charles River Laboratories has joined forces with Toxys to offer ReproTracker, a human stem cell-based in vitro assay for assessing developmental toxicity. This collaboration expands Charles River's commitment to New Approach Methodologies (NAMs) and the 3Rs (Replacement, Reduction, and Refinement).
ReproTracker can identify developmental toxicity hazards and predict teratogenic potential, serving as an early-phase screening platform or alternative to animal testing for pharmaceuticals and agrochemicals. The assay uses human embryonal stem cells, providing a more relevant model for human development.
The collaboration will accelerate the adoption of ReproTracker, as stated by Amer Jamalpoor, Chief Scientific Officer at Toxys. Elise Lewis, PhD, ATS, Principal Director and Global Lead, DART (Pharmaceuticals) at Charles River, praised the assay for enabling safe and effective developmental toxicity testing.
Charles River Laboratories and Toxys have teamed up to offer ReproTracker, a non-animal alternative for developmental toxicity testing. This collaboration reinforces Charles River's commitment to NAMs and the 3Rs, providing a more humane and relevant approach to safety assessment.
